[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629148":3},{"organization":4,"outcomesModule":7,"designInfo":68,"detailedDescription":67,"studyPopulation":67,"armGroups":74,"interventions":81,"overallOfficials":88,"centralContacts":92,"locations":97,"responsibleParty":450,"collaborators":67,"id":452,"slug":453,"hasResults":454,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":454,"sex":460,"minAge":461,"maxAge":462,"enrollmentInfo":463,"targetDuration":67,"studyType":466,"phases":467,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":100,"whyStopped":67,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":487},{"fullName":5,"class":6},"Pfizer","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":67},[9],{"measure":10,"description":11,"timeFrame":12},"Number and percent of enrolled participants with clinical remission based on Modified Mayo Score (MMS) at Week 52","Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point (SF= 1 or 0), ES=1 or 0 and RB=0. Mayo score: instrument designed to measure disease activity of ulcerative colitis. will be summarized by the number and percentage of participants achieving the response, along with a two-sided 95% CI.","Week 52",[14,17,20,22,25,27,30,33,36,40,43,47,48,52,56,59,63],{"measure":15,"description":11,"timeFrame":16},"Number and percent of enrolled participants with clinical remission based on MMS at Week 12","Week 12",{"measure":18,"description":19,"timeFrame":16},"Number and percent of enrolled participants with clinical response based on MMS score components at Week 12","Clinical response was defined as a ≥2-point and ≥30% decrease from baseline in MMS, and a ≥1-point decrease from baseline in RB subscore or an absolute RB subscore ≤ 1. These results will be summarized by the number and percentage of participants achieving the response, along with a two-sided 95% CI.",{"measure":21,"description":19,"timeFrame":12},"Number and percent of enrolled participants with clinical response based on MMS score components at Week 52",{"measure":23,"description":24,"timeFrame":16},"Number and percent of enrolled participants endoscopic improvement based on MMS score components at Week 12","Endoscopic improvement defined as ES ≤1 (excluding friability). These results will be summarized by the number and percentage of participants achieving the response, along with a two-sided 95% CI.",{"measure":26,"description":24,"timeFrame":12},"Number and percent of enrolled participants endoscopic improvement based on MMS score components at Week 52",{"measure":28,"description":29,"timeFrame":16},"Number and percent of enrolled participants Clinical remission at Week 12 and who had not been receiving corticosteroids for ≥2 weeks immediately prior to Week 12","Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point (SF= 1 or 0), ES=1 or 0 and RB=0. Number of weeks off corticosteroids prior to week 12 visit will be used to determine end point. Mayo score: instrument designed to measure disease activity of ulcerative colitis. These results will be summarized by the number and percentage of participants achieving the response, along with a two-sided 95% CI.",{"measure":31,"description":32,"timeFrame":12},"Number and percent of enrolled participants Clinical remission at Week 52 and who had not been receiving corticosteroids for ≥12 weeks immediately prior to Week 52","Clinical remission was defined as a total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point (SF= 1 or 0), ES=1 or 0 and RB=0. Number of weeks off corticosteroids prior to week 52 visit will be used to determine end point. Mayo score: instrument designed to measure disease activity of ulcerative colitis. These results will be summarized by the number and percentage of participants achieving the response, along with a two-sided 95% CI.",{"measure":34,"description":35,"timeFrame":12},"Number and percent of enrolled participants Symptomatic remission at all time points up to Week 52","Symptomatic remission was defined as SF subscore = 0 or 1 and an RB subscore = 0. These results will be summarized by the number and percentage of participants achieving the response, along with a two-sided 95% CI.",{"measure":37,"description":38,"timeFrame":39},"Number and percent of enrolled participants Pediatric Ulcerative Colitis Activity Index (PUCAI) clinical remission from baseline to Week 260","Clinical remission by PUCAI is defined as a score \\\u003C10. These assessments will be conducted at each visit. These results will be summarized by the number and percentage of participants achieving the response, along with a two-sided 95% CI.","Baseline, through Week 260",{"measure":41,"description":42,"timeFrame":39},"Number and percent of enrolled participants PUCAI clinical response from baseline to Week 260","Clinical response by PUCAI is defined as a score ≥ 20 point reduction from baseline. These assessments will be conducted at each visit.These results will be summarized by the number and percentage of participants achieving the response, along with a two-sided 95% CI.",{"measure":44,"description":45,"timeFrame":46},"Number and percentage of participants reporting a positive taste\u002Fpalatability score","The responses to taste acceptability questionnaire on etrasimod tablets and granules will be summarized using count and percentage for SAS","Week 2",{"measure":44,"description":45,"timeFrame":16},{"measure":49,"description":50,"timeFrame":51},"Change from baseline in Z-Scores height and weight","These assessments will be conducted at each visit. The values and change from baseline will be summarized using number of observations, mean, standard deviation, minimum and maximum values by visit for SAS.","Baseline through Week 260",{"measure":53,"description":54,"timeFrame":55},"Number of Participants with Treatment Emergent Treatment-Related Adverse Events (AEs), including Serious Adverse Events (SAEs) and AEs leading to discontinuation.","Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability\u002Fincapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to etrasimod was assessed by the investigator (Yes\u002FNo). Participants with multiple occurrences of an AE within a category were counted once within the category.","Baseline up to 28 days after last dose of study intervention",{"measure":57,"description":58,"timeFrame":55},"Number of Participants with Clinically Significant Findings in Laboratory Examinations","Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); Hepatobiliary biochemistry: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Albumin, Alkaline Phosphatase, Total Bilirubin ; Renal Function Tests: Blood Urea Nitrogen (BUN), Creatinine, Creatinine Kinase, Uric Acid ; Electrolytes: Sodium, Potassium; Glucose; Urine analysis: (decimal logarithm of reciprocal of hydrogen ion activity )\\[pH\\], Specific gravity. Clinically significant laboratory abnormality findings were based on investigator discretion.",{"measure":60,"description":61,"timeFrame":62},"Number of Participants with Clinically Significant Change in Vital Signs","Following vital sign parameters were assessed: diastolic blood pressure, systolic blood pressure, respiration rate, pulse rate, temperature and body weight. Number of participants with clinically significant change in any vital sign parameter compared to baseline were reported. Clinically significant change in vital signs criteria were based on investigator's discretion.","Baseline up to week 260",{"measure":64,"description":65,"timeFrame":66},"Plasma concentration verses time of study intervention","Samples collected prior to daily dosing of study intervention for measurement of plasma concentrations of etrasimod will be analyzed using a validated analytical method in compliance with applicable SOPs.","Baseline, Weeks 2 and 4",null,{"allocation":69,"interventionModel":70,"interventionModelDescription":67,"primaryPurpose":71,"observationalModel":67,"timePerspective":67,"maskingInfo":72},"NA","SINGLE_GROUP","TREATMENT",{"masking":73,"maskingDescription":67,"whoMasked":67},"NONE",[75],{"label":76,"type":77,"description":78,"interventionNames":79},"Etrasimod","EXPERIMENTAL","Etrasimod by mouth, once daily up to 52 weeks",[80],"Drug: Etrasimod",[82],{"type":83,"name":76,"description":84,"armGroupLabels":85,"otherNames":86},"DRUG","Once daily by mouth",[76],[87],"APD334",[89],{"name":90,"affiliation":5,"role":91},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[93],{"name":90,"role":94,"phone":95,"phoneExt":67,"email":96},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",[98,111,116,121,126,131,136,141,153,163,174,186,192,202,214,223,235,245,254,263,270,279,284,293,302,308,313,316,328,337,347,354,363,372,384,390,399,405,417,426,435,441],{"facility":99,"status":100,"city":101,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":110,"contacts":67},"Fink Children's Ambulatory Care Center","RECRUITING","New York","10016","United States","US",{"type":106,"coordinates":107},"Point",[108,109],-74.00597,40.71427,{"lat":109,"lon":108},{"facility":112,"status":100,"city":101,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":113,"geoPoint":115,"contacts":67},"Kimmel Pavilion - NYU Langone",{"type":106,"coordinates":114},[108,109],{"lat":109,"lon":108},{"facility":117,"status":100,"city":101,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":118,"geoPoint":120,"contacts":67},"NYU Grossman School of Medicine",{"type":106,"coordinates":119},[108,109],{"lat":109,"lon":108},{"facility":122,"status":100,"city":101,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":123,"geoPoint":125,"contacts":67},"NYU Langone Health (Tisch Hospital)",{"type":106,"coordinates":124},[108,109],{"lat":109,"lon":108},{"facility":127,"status":100,"city":101,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":128,"geoPoint":130,"contacts":67},"NYU Langone Inflammatory Bowel Disease Center",{"type":106,"coordinates":129},[108,109],{"lat":109,"lon":108},{"facility":132,"status":100,"city":101,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":133,"geoPoint":135,"contacts":67},"NYU Langone Radiology - Tisch Hospital",{"type":106,"coordinates":134},[108,109],{"lat":109,"lon":108},{"facility":137,"status":100,"city":101,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":138,"geoPoint":140,"contacts":67},"NYU Medical Science Building (MSB)",{"type":106,"coordinates":139},[108,109],{"lat":109,"lon":108},{"facility":142,"status":100,"city":143,"state":144,"zip":145,"country":146,"countryCode":147,"cosmosGeoPoint":148,"geoPoint":152,"contacts":67},"The Children's Hospital at Westmead","Westmead","New South Wales","2145","Australia","AU",{"type":106,"coordinates":149},[150,151],150.98768,-33.80383,{"lat":151,"lon":150},{"facility":154,"status":100,"city":155,"state":156,"zip":157,"country":146,"countryCode":147,"cosmosGeoPoint":158,"geoPoint":162,"contacts":67},"Monash Health","Clayton","Victoria","3168",{"type":106,"coordinates":159},[160,161],145.11667,-37.91667,{"lat":161,"lon":160},{"facility":164,"status":165,"city":166,"state":167,"zip":168,"country":146,"countryCode":147,"cosmosGeoPoint":169,"geoPoint":173,"contacts":67},"Perth Children's Hospital","NOT_YET_RECRUITING","Perth","Western Australia","6009",{"type":106,"coordinates":170},[171,172],115.8614,-31.95224,{"lat":172,"lon":171},{"facility":175,"status":100,"city":176,"state":177,"zip":178,"country":179,"countryCode":180,"cosmosGeoPoint":181,"geoPoint":185,"contacts":67},"Health Sciences Centre Winnipeg","Winnipeg","Manitoba","R3A 1S1","Canada","CA",{"type":106,"coordinates":182},[183,184],-97.14704,49.8844,{"lat":184,"lon":183},{"facility":187,"status":100,"city":176,"state":177,"zip":188,"country":179,"countryCode":180,"cosmosGeoPoint":189,"geoPoint":191,"contacts":67},"Children's Hospital Research Institute of Manitoba","R3E 3P4",{"type":106,"coordinates":190},[183,184],{"lat":184,"lon":183},{"facility":193,"status":100,"city":194,"state":195,"zip":196,"country":179,"countryCode":180,"cosmosGeoPoint":197,"geoPoint":201,"contacts":67},"CHU de Québec - Université Laval","Québec","Quebec","G1V4G2",{"type":106,"coordinates":198},[199,200],-71.21454,46.81228,{"lat":200,"lon":199},{"facility":203,"status":100,"city":204,"state":205,"zip":206,"country":207,"countryCode":208,"cosmosGeoPoint":209,"geoPoint":213,"contacts":67},"Hospices Civils de Lyon - Hôpital Femme Mère Enfant","Bron","Auvergne-Rhône-Alpes","69500","France","FR",{"type":106,"coordinates":210},[211,212],4.91303,45.73865,{"lat":212,"lon":211},{"facility":215,"status":100,"city":216,"state":67,"zip":217,"country":207,"countryCode":208,"cosmosGeoPoint":218,"geoPoint":222,"contacts":67},"Hôpital Universitaire Necker Enfants Malades","Paris","75015",{"type":106,"coordinates":219},[220,221],2.3488,48.85341,{"lat":221,"lon":220},{"facility":224,"status":100,"city":225,"state":226,"zip":227,"country":228,"countryCode":229,"cosmosGeoPoint":230,"geoPoint":234,"contacts":67},"Universitätsklinikum Münster - Albert Schweitzer Campus","Münster","North Rhine-Westphalia","48149","Germany","DE",{"type":106,"coordinates":231},[232,233],7.62571,51.96236,{"lat":233,"lon":232},{"facility":236,"status":100,"city":237,"state":238,"zip":239,"country":228,"countryCode":229,"cosmosGeoPoint":240,"geoPoint":244,"contacts":67},"Universitätsklinikum Leipzig","Leipzig","Saxony","04103",{"type":106,"coordinates":241},[242,243],12.37129,51.33962,{"lat":243,"lon":242},{"facility":246,"status":100,"city":247,"state":67,"zip":248,"country":228,"countryCode":229,"cosmosGeoPoint":249,"geoPoint":253,"contacts":67},"Universitaetsklinikum Tuebingen","Tübingen","72076",{"type":106,"coordinates":250},[251,252],9.05222,48.52266,{"lat":252,"lon":251},{"facility":255,"status":100,"city":256,"state":67,"zip":257,"country":228,"countryCode":229,"cosmosGeoPoint":258,"geoPoint":262,"contacts":67},"HELIOS Klinikum Wuppertal","Wuppertal","42283",{"type":106,"coordinates":259},[260,261],7.14816,51.25627,{"lat":261,"lon":260},{"facility":264,"status":100,"city":265,"state":266,"zip":267,"country":268,"countryCode":269,"cosmosGeoPoint":67,"geoPoint":67,"contacts":67},"Sheba Medical Center","Ramat Gan","Central District","5262100","Israel","IL",{"facility":271,"status":100,"city":272,"state":266,"zip":273,"country":268,"countryCode":269,"cosmosGeoPoint":274,"geoPoint":278,"contacts":67},"Kaplan Medical Center Pharmacy","Rehovot","7610001",{"type":106,"coordinates":275},[276,277],34.81199,31.89421,{"lat":277,"lon":276},{"facility":280,"status":100,"city":272,"state":266,"zip":273,"country":268,"countryCode":269,"cosmosGeoPoint":281,"geoPoint":283,"contacts":67},"Kaplan Medical Center",{"type":106,"coordinates":282},[276,277],{"lat":277,"lon":276},{"facility":285,"status":100,"city":286,"state":266,"zip":287,"country":268,"countryCode":269,"cosmosGeoPoint":288,"geoPoint":292,"contacts":67},"Yitzhak Shamir Medical Center","Ẕerifin","70300",{"type":106,"coordinates":289},[290,291],34.84852,31.95731,{"lat":291,"lon":290},{"facility":294,"status":100,"city":295,"state":295,"zip":296,"country":268,"countryCode":269,"cosmosGeoPoint":297,"geoPoint":301,"contacts":67},"Shaare Zedek Medical Center","Jerusalem","9013102",{"type":106,"coordinates":298},[299,300],35.21633,31.76904,{"lat":300,"lon":299},{"facility":303,"status":100,"city":295,"state":295,"zip":304,"country":268,"countryCode":269,"cosmosGeoPoint":305,"geoPoint":307,"contacts":67},"Hadassah Medical Center","9112001",{"type":106,"coordinates":306},[299,300],{"lat":300,"lon":299},{"facility":309,"status":100,"city":310,"state":311,"zip":312,"country":268,"countryCode":269,"cosmosGeoPoint":67,"geoPoint":67,"contacts":67},"Rambam Health Care Campus","Haifa","Northern District","3109601",{"facility":314,"status":100,"city":310,"state":311,"zip":315,"country":268,"countryCode":269,"cosmosGeoPoint":67,"geoPoint":67,"contacts":67},"Carmel Medical Center","3436212",{"facility":317,"status":100,"city":318,"state":319,"zip":320,"country":321,"countryCode":322,"cosmosGeoPoint":323,"geoPoint":327,"contacts":67},"Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII","Bergamo","Lombardy","24127","Italy","IT",{"type":106,"coordinates":324},[325,326],9.66721,45.69601,{"lat":326,"lon":325},{"facility":329,"status":165,"city":330,"state":319,"zip":331,"country":321,"countryCode":322,"cosmosGeoPoint":332,"geoPoint":336,"contacts":67},"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","Milan","20122",{"type":106,"coordinates":333},[334,335],9.18951,45.46427,{"lat":335,"lon":334},{"facility":338,"status":165,"city":339,"state":340,"zip":341,"country":321,"countryCode":322,"cosmosGeoPoint":342,"geoPoint":346,"contacts":67},"Azienda Ospedaliera Universitaria Meyer IRCCS","Florence","Tuscany","50139",{"type":106,"coordinates":343},[344,345],11.24626,43.77925,{"lat":345,"lon":344},{"facility":348,"status":100,"city":349,"state":350,"zip":351,"country":352,"countryCode":353,"cosmosGeoPoint":67,"geoPoint":67,"contacts":67},"Saitama Prefectural Children's Medical Center","Saitama-shi","Saitama","330-8777","Japan","JP",{"facility":355,"status":100,"city":356,"state":67,"zip":357,"country":352,"countryCode":353,"cosmosGeoPoint":358,"geoPoint":362,"contacts":67},"Japanese Red Cross Kumamoto Hospital","Kumamoto","861-8520",{"type":106,"coordinates":359},[360,361],130.69181,32.80589,{"lat":361,"lon":360},{"facility":364,"status":100,"city":365,"state":67,"zip":366,"country":352,"countryCode":353,"cosmosGeoPoint":367,"geoPoint":371,"contacts":67},"Juntendo University Hospital","Tokyo","113-8431",{"type":106,"coordinates":368},[369,370],139.69171,35.6895,{"lat":370,"lon":369},{"facility":373,"status":100,"city":374,"state":375,"zip":376,"country":377,"countryCode":378,"cosmosGeoPoint":379,"geoPoint":383,"contacts":67},"Centrum Zdrowia MDM","Warsaw","Masovian Voivodeship","00-189","Poland","PL",{"type":106,"coordinates":380},[381,382],21.01178,52.22977,{"lat":382,"lon":381},{"facility":385,"status":100,"city":374,"state":375,"zip":386,"country":377,"countryCode":378,"cosmosGeoPoint":387,"geoPoint":389,"contacts":67},"Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś","04-501",{"type":106,"coordinates":388},[381,382],{"lat":382,"lon":381},{"facility":391,"status":100,"city":392,"state":67,"zip":393,"country":377,"countryCode":378,"cosmosGeoPoint":394,"geoPoint":398,"contacts":67},"Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero","Katowice","40-600",{"type":106,"coordinates":395},[396,397],19.02173,50.2597,{"lat":397,"lon":396},{"facility":400,"status":100,"city":374,"state":67,"zip":401,"country":377,"countryCode":378,"cosmosGeoPoint":402,"geoPoint":404,"contacts":67},"Instytut \"Pomnik - Centrum Zdrowia Dziecka\"","04-730",{"type":106,"coordinates":403},[381,382],{"lat":382,"lon":381},{"facility":406,"status":100,"city":407,"state":408,"zip":409,"country":410,"countryCode":411,"cosmosGeoPoint":412,"geoPoint":416,"contacts":67},"King's College Hospital","London","London, CITY of","SE5 9RL","United Kingdom","UK",{"type":106,"coordinates":413},[414,415],-0.12574,51.50853,{"lat":415,"lon":414},{"facility":418,"status":165,"city":419,"state":67,"zip":420,"country":410,"countryCode":411,"cosmosGeoPoint":421,"geoPoint":425,"contacts":67},"Bristol Royal Hospital for Children","Bristol","BS2 8BJ",{"type":106,"coordinates":422},[423,424],-2.59665,51.45523,{"lat":424,"lon":423},{"facility":427,"status":100,"city":428,"state":67,"zip":429,"country":410,"countryCode":411,"cosmosGeoPoint":430,"geoPoint":434,"contacts":67},"Alder Hey Children's Hospital","Liverpool","L14 5AB",{"type":106,"coordinates":431},[432,433],-2.97794,53.41058,{"lat":433,"lon":432},{"facility":436,"status":100,"city":407,"state":67,"zip":437,"country":410,"countryCode":411,"cosmosGeoPoint":438,"geoPoint":440,"contacts":67},"Evelina London Children's Hospital","SE1 7EH",{"type":106,"coordinates":439},[414,415],{"lat":415,"lon":414},{"facility":442,"status":100,"city":443,"state":67,"zip":444,"country":410,"countryCode":411,"cosmosGeoPoint":445,"geoPoint":449,"contacts":67},"Sheffield Children's Hospital","Sheffield","S10 2TH",{"type":106,"coordinates":446},[447,448],-1.4659,53.38297,{"lat":448,"lon":447},{"type":451,"investigatorFullName":67,"investigatorTitle":67,"investigatorAffiliation":67,"oldNameTitle":67,"oldOrganization":67},"SPONSOR","100629148","phase-2-a-study-of-how-the-medicine-called-etrasimod-works-in-children-with-the-gut-disease-called-ulcerative-colitis-100629148",false,"NCT07470879","A Study of How the Medicine Called \"Etrasimod\" Works in Children With the Gut Disease Called Ulcerative Colitis","A PHASE 2 OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, AND SAFETY OF ETRASIMOD IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS","ELEVATE-UCkids","Inclusion criteria:\n\nHave a diagnosis of ulcerative colitis (UC) that is moderately to severely active Participants are permitted to be receiving a therapeutic dose of select UC therapies\n\nExclusion criteria:\n\nSevere extensive colitis Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis","ALL","2 Years","11 Years",{"count":464,"type":465},24,"ESTIMATED","INTERVENTIONAL",[468],"PHASE2","The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in pediatrics participants (≥ 2 years up to \\\u003C 12 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).",[471],"Colitis, Ulcerative",[473,474,475,476,477],"ulcerative","colitis","ulcerative colitis","etrasimod","pediatrics","2026-08-21",{"date":480,"type":481},"2026-08-24","ACTUAL",{"date":483,"type":481},"2026-05-28",{"date":485,"type":465},"2034-08-18",{"name":5,"class":6},42]